The drug in question, called firicabtagene autoleucel or firi-cel, is an autologous CD22 CAR-T cell therapy that had been ...
CAR T–focused biotech Cargo Therapeutics surprised and disappointed analysts when it announced that it would discontinue a ...
an allogeneic CAR T-cell therapy targeting CD19/CD20, has administered the first dose to a patient in an investigator-initiated trial (IIT). KJ-C2219 is developed based on CARsgen's THANK-u Plus ...
NEW YORK, NY / ACCESS Newswire / February 3, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...
在抗击癌症的战斗中，您会好奇一项新的治疗方法是如何改变患者命运的吗？最近，成都优赛诺生物科技有限公司成功研发的靶向CD19嵌合抗原受体（CAR）异体通用型T细胞注射液（UC101）如同一束曙光，打破了CAR-T治疗的传统界限。这是全球首款通过美国食品药品监督管理局（FDA）新药临床试验（IND）申请的脐血通用型CAR-T产品，标志着中国在细胞治疗领域迈出了重要一步。
Hosted on MSN18d
Autolus presents new data on CAR-T therapy cost benefitsAUCATZYL® is their proprietary CD19-directed CAR T cell therapy, designed to minimize the activation of programmed T cells, potentially improving safety compared to existing CD19 CAR T therapies.
The changes will extend the company's cash runway, enabling it to advance a tri-specific CAR T-cell candidate and its allogeneic cell therapy platform.
Cabaletta Bio, Inc.'s CD19-directed CAR T-cell therapy shows early promise in treating autoimmune diseases, despite limited patient numbers and follow-up time. Financially, Cabaletta Bio has ...
an allogeneic CAR T-cell therapy targeting CD19/CD20, has administered the first dose to a patient in an investigator-initiated trial (IIT). KJ-C2219 is developed based on CARsgen's THANK-u Plus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback